Literature DB >> 26302335

Role of GRP78 in promoting therapeutic-resistant breast cancer.

Katherine L Cook1,2, Robert Clarke1.   

Abstract

Over 230,000 new cases of invasive breast cancer are diagnosed annually within the USA. Recurrent breast cancer remains a mostly incurable disease with drug resistance, tumor latency and distant metastases driving breast tumor recurrence and morbidity. Understanding drug resistance is a critical component of combating breast cancer. Recently, the protein chaperone GRP78 and the unfolded protein response were implicated as drivers of drug resistance. Preclinical studies show inhibiting GRP78 can reverse drug resistance. Furthermore, drugs developed to target GRP78 show clinical promise in several ongoing clinical trials.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26302335      PMCID： PMC4600199          DOI： 10.4155/FMC.15.80

Source DB:  PubMed          Journal:  Future Med Chem        ISSN： 1756-8919            Impact factor:   3.808


  29 in total

Review 1.  Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer.

Authors:  Rebecca B Riggins; Amy H Bouton; Minetta C Liu; Robert Clarke
Journal:  Vitam Horm       Date:  2005       Impact factor: 3.421

2.  GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer.

Authors:  Eunjung Lee; Peter Nichols; Darcy Spicer; Susan Groshen; Mimi C Yu; Amy S Lee
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

3.  Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions.

Authors:  P M Fernandez; S O Tabbara; L K Jacobs; F C Manning; T N Tsangaris; A M Schwartz; K A Kennedy; S R Patierno
Journal:  Breast Cancer Res Treat       Date:  2000-01       Impact factor: 4.872

4.  Characterization and mechanism of stress-induced translocation of 78-kilodalton glucose-regulated protein (GRP78) to the cell surface.

Authors:  Yuan-Li Tsai; Yi Zhang; Chun-Chih Tseng; Ramunas Stanciauskas; Fabien Pinaud; Amy S Lee
Journal:  J Biol Chem       Date:  2015-02-11       Impact factor: 5.157

5.  GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth.

Authors:  Gidi Shani; Wolfgang H Fischer; Nicholas J Justice; Jonathan A Kelber; Wylie Vale; Peter C Gray
Journal:  Mol Cell Biol       Date:  2007-11-08       Impact factor: 4.272

6.  Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab.

Authors:  Alejandro Vazquez-Martin; Cristina Oliveras-Ferraros; Javier A Menendez
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

7.  GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis.

Authors:  Yong Fu; Jianze Li; Amy S Lee
Journal:  Cancer Res       Date:  2007-04-15       Impact factor: 12.701

8.  New glycosylated derivatives of versipelostatin, the GRP78/Bip molecular chaperone down-regulator, from Streptomyces versipellis 4083-SVS6.

Authors:  Ping Zhao; Jun-ya Ueda; Ikuko Kozone; Shuhei Chijiwa; Motoki Takagi; Fumitaka Kudo; Makoto Nishiyama; Kazuo Shin-ya; Tomohisa Kuzuyama
Journal:  Org Biomol Chem       Date:  2009-02-26       Impact factor: 3.876

Review 9.  HER2 therapy: molecular mechanisms of trastuzumab resistance.

Authors:  Rita Nahta; Francisco J Esteva
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

10.  Activation and clinical significance of the unfolded protein response in breast cancer.

Authors:  P Scriven; S Coulson; R Haines; S Balasubramanian; S Cross; L Wyld
Journal:  Br J Cancer       Date:  2009-10-27       Impact factor: 7.640
View more
  20 in total

Review 1.  Targeting the unfolded protein response in cancer.

Authors:  Rani Ojha; Ravi K Amaravadi
Journal:  Pharmacol Res       Date:  2017-04-08       Impact factor: 7.658

2.  High levels of unfolded protein response component CHAC1 associates with cancer progression signatures in malignant breast cancer tissues.

Authors:  Vikrant Mehta; Prabhat Suman; Harish Chander
Journal:  Clin Transl Oncol       Date:  2022-08-05       Impact factor: 3.340

Review 3.  Estrogen Receptor and the Unfolded Protein Response: Double-Edged Swords in Therapy for Estrogen Receptor-Positive Breast Cancer.

Authors:  Ping Fan; V Craig Jordan
Journal:  Target Oncol       Date:  2022-03-15       Impact factor: 4.864

4.  Insulin-like growth factor 1-receptor signaling stimulates GRP78 expression through the PI3K/AKT/mTOR/ATF4 axis.

Authors:  Dat P Ha; Amy S Lee
Journal:  Cell Signal       Date:  2020-08-14       Impact factor: 4.315

Review 5.  PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.

Authors:  Veronica Vella; Maria Luisa Nicolosi; Stefania Giuliano; Maria Bellomo; Antonino Belfiore; Roberta Malaguarnera
Journal:  Front Endocrinol (Lausanne)       Date:  2017-02-22       Impact factor: 5.555

6.  Discovering a Reliable Heat-Shock Factor-1 Inhibitor to Treat Human Cancers: Potential Opportunity for Phytochemists.

Authors:  Murugesan Velayutham; Arturo J Cardounel; Zhenguo Liu; Govindasamy Ilangovan
Journal:  Front Oncol       Date:  2018-04-06       Impact factor: 6.244

7.  Glucose-Related Protein 78 Expression and Its Effects on Cisplatin-Resistance in Cervical Cancer.

Authors:  Chengyan Luo; Wen Fan; Yi Jiang; Shulin Zhou; Wenjun Cheng
Journal:  Med Sci Monit       Date:  2018-04-13

8.  Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.

Authors:  Xiangyu Zhang; Zelai He; Longquan Xiang; Liang Li; Haiyan Zhang; Fanzhong Lin; Hongying Cao
Journal:  Drug Des Devel Ther       Date:  2019-04-29       Impact factor: 4.162

9.  Unfolded protein response signaling impacts macrophage polarity to modulate breast cancer cell clearance and melanoma immune checkpoint therapy responsiveness.

Authors:  David R Soto-Pantoja; Adam S Wilson; Kenysha Yj Clear; Brian Westwood; Pierre L Triozzi; Katherine L Cook
Journal:  Oncotarget       Date:  2017-08-03

10.  miR‑495 enhances the efficacy of radiotherapy by targeting GRP78 to regulate EMT in nasopharyngeal carcinoma cells.

Authors:  Xueping Feng; Wuwu Lv; Shuanglian Wang; Qian He
Journal:  Oncol Rep       Date:  2018-07-02       Impact factor: 3.906
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.